The drug maker says its treatment of a rare kidney disease met its main goal in a late-stage trial.

The stock looks like a great pick to help turn investors into multimillionaires, given enough time. Everyone should save ...

Vertex stock jumps after interim phase III data show povetacicept cuts proteinuria 52% in IgA nephropathy study and boost hopes for accelerated FDA approval.

Vertex Pharmaceuticals (NASDAQ:VRTX) shares rose 6% to $488.52 in premarket trading Thursday after the company reported successful results from a late-stage trial ...

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals (NASDAQ: VRTX) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth ...

I’m upgrading Vertex to a "Neutral" rating after its sharp stock decline corrected prior valuation concerns, but risks remain substantial. Vertex balances mid-teens revenue growth with high-teens ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) will report its first-quarter earnings on Monday. As the company reports after market hours, Wall Street expects $4.32 in EPS and $2.85 billion in revenues.

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 3.57% to $460.82 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.56% to ...

As of February 17, 2026, shares were priced at $12.34, down 74.09% over the prior year. The position was previously 11.8% of the fund's AUM as of the prior quarter. Vertex is a leading provider of tax ...

Turning $100,000 into $1 million in a decade requires a compound annual growth rate (CAGR) of almost 26%. That's miles above the market's long-term average. It's also even better than a company like ...